Paper Details

  1. Home
  2. Paper Details

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.

Author: BasuSupratik, BeksacMeral, CarsonRobin, CookGordon, DelioukinaMaria, GriesKatharine S, KudvaAnupa, MateosMaria-Victoria, PeiHuiling, RigaudeauSophie, SchotsRik, SpickaIvan, TrompBrenda, Van RampelberghRian, WhiteDarrell, WrobelTomasz, WroblewskiSusan

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) is more effective than standard treatments for transplant-ineligible newly diagnosed multiple myeloma. Patients can switch from DARA IV to subcutaneous daratumumab (DARA SC) while on daratumumab monotherapy in ALCYONE or daratumumab plus Rd in MAIA. DARA SC has been shown to be noninferior to DARA IV and reduces administration time, allowing patients to spend less time in healthcare settings.
Paper Details　
Original Abstract of the Article :
Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible newly diagnosed multiple myeloma. In these studies, patients coul...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/10781552221103551

データ提供：米国国立医学図書館（NLM）

Easing the Burden of Multiple Myeloma: Exploring the Benefits of Subcutaneous Daratumumab

In the complex world of cancer research, we're constantly striving to improve patient outcomes. This study delves into the realm of multiple myeloma treatment, examining the [研究手法] of [主な目的]. The researchers, like skilled desert guides, aimed to [主要な目的] by comparing [研究手法]. Their findings shed light on the potential of [研究手法] as a safe and effective alternative, offering a more convenient treatment option for patients. This research adds a valuable layer to our understanding of multiple myeloma treatment, potentially leading to improved patient care. The study's [特筆すべき結果や意義] highlights the significance of patient preference in treatment decisions.

A More Convenient Approach for Multiple Myeloma Treatment

The study's findings suggest that [研究結果] might offer a significant advantage for patients. This approach could potentially reduce treatment time, increase convenience, and improve patient quality of life. The study's results, like a guiding star in the night sky, point towards a brighter future for patients with multiple myeloma.

Navigating the Sands of Cancer Treatment

Cancer treatment can be a challenging journey, but there are ways to make it more manageable. Staying informed about your treatment options, discussing your preferences with your healthcare team, and seeking support from loved ones can all make a difference. This study reminds us that patient well-being should be at the forefront of every treatment decision.

Dr.Camel's Conclusion

This study is like a refreshing oasis in the desert of cancer treatment. It reveals that [研究結果] could offer a more convenient and patient-centered approach to multiple myeloma. By prioritizing patient comfort and preference, we can empower individuals to actively participate in their treatment journey, fostering hope and resilience in the face of adversity.
Date :
  1. Date Completed 2023-06-28
  2. Date Revised 2023-06-28
Further Info :

Pubmed ID

36067063

DOI: Digital Object Identifier

10.1177/10781552221103551

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.